BioHarvest Sciences (BHST)
NASDAQ:BHST
Want to see BHST full AI Analyst Report?
Earnings Data
Report Date
Jun 03, 2026TBA (Not Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
―Last Year’s EPS
-0.13Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum: robust revenue growth (Q4 +25%, FY +37%), improved margins, positive adjusted EBITDA in Q4, a materially stronger cash position, successful product launch traction (VINIA BloodFlow Hydration), expanding D2C scale and market leadership, and tangible scientific and commercial progress in the CDMO pipeline (notably a claimed first-ever Stage 1 fragrance cell culture with retained ownership). Management also outlined deliberate investments to scale CDMO capabilities and to premiumize the VINIA portfolio. Near-term challenges include continued GAAP losses, higher absolute operating spend for growth, modest third-party CDMO revenue today and long development timelines, channel concentration risks, and geopolitical supply‑chain uncertainty. On balance, the highlights (growth, margin improvement, cash build, product and R&D breakthroughs, and scalable go-to-market shifts) outweigh the lowlights, supporting an overall positive outlook for 2026 and beyond.Company Guidance
Strong Revenue Growth
Q4 2025 revenues of $9.1M, up 25% year-over-year; full-year 2025 revenues of $34.5M, up 37% versus prior year.
Improving Profitability Metrics
Q4 gross profit rose 27% to $5.2M and gross margin improved to 58% (up 100 bps YoY); full-year gross margin was 59% (up 400 bps YoY). Adjusted EBITDA turned positive to $0.5M in Q4 versus an adjusted EBITDA loss of $1.8M in the year-ago quarter.
Material Cash Position Improvement
Cash and cash equivalents increased to $23.0M as of Dec 31, 2025, up from $2.4M a year earlier (approximately +858%), strengthening the balance sheet to support 2026 investments.
VINIA D2C Momentum and Market Leadership
VINIA direct-to-consumer business generated $30.6M in U.S. revenue for the full year and VINIA was named the #1 Resveratrol polyphenol brand in the U.S. (Nielsen IQ 2025 + Amazon data); the brand exceeded 85,000 active users as of March 2026.
Successful Launch: VINIA BloodFlow Hydration
Launched Dec 3, 2025—within ~16 weeks achieved: #2 contributor to incremental new customer sales (15% of new-customer revenue YTD on vinia.com), site rating 4.8/5 (>90 reviews), Amazon rating 4.9/5 (~50 reviews), and achieving ~50% premium pricing vs market leaders; early consumer challenge enrolled >1,300 participants.
Improved Operating-Leverage Trends
Total operating expenses rose in absolute terms to $6.3M in Q4 from $5.8M a year ago but shrank as a percentage of revenue to 70% from 80%, indicating better operating leverage.
CDMO Scientific Breakthroughs and Pipeline Progress
CDMO completed Stage 1 for a rare, endangered fragrance plant (first-ever stable cell culture claimed) with molecular profiles matching the original plant; company retains 20% ownership in developed compositions. Other programs: pharma Stage 1 complete with Stage 2 progress, saffron and nutrition programs advancing; internal assets (pomegranate PGG, blueberry polyphenols, exosomes) progressing as de-risked pipeline.
CDMO Commercial Traction and 2026 Revenue Ambition
CDMO delivered ~ $2M in third-party revenue in 2025 (≈$9M total if including internal manufacturing), and management guided external CDMO revenue for 2026 of $4M–$6M, implying meaningful expected acceleration (2x–3x).
Go-to-Market Enhancements
Marketing mix shift away from TV toward digital (Facebook, Instagram, YouTube, TikTok) and scaling a Health Pros channel (250 partners, adding 25–50/month) that delivered >10% of incremental new-customer revenue in March—expected to improve customer acquisition costs and broaden demographics.
BHST Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BHST Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 31, 2026 | $4.34 | $4.31 | -0.69% |
Nov 13, 2025 | $7.30 | $7.23 | -0.96% |
Aug 11, 2025 | $8.76 | $8.82 | +0.68% |
May 15, 2025 | $6.43 | $6.50 | +1.09% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does BioHarvest Sciences (BHST) report earnings?
BioHarvest Sciences (BHST) is schdueled to report earning on Jun 03, 2026, TBA (Not Confirmed).
What is BioHarvest Sciences (BHST) earnings time?
BioHarvest Sciences (BHST) earnings time is at Jun 03, 2026, TBA (Not Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BHST EPS forecast?
Currently, no data Available